• Nifedipine: An Assay Lens on Calcium and CYP

  2026-09-04

  Nifedipine (BAY-a-1040) is more than an L-type calcium channel blocker: it can serve as a controlled perturbation for separating calcium-dependent phenotypes from broader hepatic adaptation. This article connects calcium influx inhibition with CYP activity, iron metabolism modulation, and assay design while clearly distinguishing established evidence from exploratory interpretation.

• Deferasirox in Iron-Stress and Lysosomal Assays

  2026-09-04

  Deferasirox is an oral iron chelator that can be repurposed as a controlled laboratory probe for iron availability, oxidative stress, and nutrient-starvation phenotypes. This workflow connects deferasirox exposure with the TCF25–V-ATPase–ferritinophagy axis while separating lysosomal cell death from apoptosis and nonspecific toxicity.

• M344: From HDAC Biology to Translational Strategy

  2026-09-03

  M344 illustrates how chromatin-directed pharmacology can connect histone acetylation to differentiation, proliferation control, apoptosis, tumor response, and viral latency research. This thought-leadership guide translates mechanistic and preclinical evidence into practical study-design decisions without overstating clinical readiness.

• Mavorixafor in WHIM Syndrome: Phase 3 Evidence

  2026-09-03

  The reference article highlights phase 3 evidence that oral CXCR4 antagonism with mavorixafor can improve neutrophil and lymphocyte availability in patients with WHIM syndrome. The findings support mechanism-based treatment for this rare immunodeficiency while leaving important questions about long-term safety, immune normalization, and cancer risk.

• CXCR4 Theranostics in Lymphoma: Evidence and Limits

  2026-09-02

  The 2026 review by Dhamecha and colleagues presents CXCR4 as a bridge between lymphoma biology, molecular imaging, and targeted treatment. Its central implication is that CXCR4 expression may support both disease characterization and therapeutic selection, although physiological uptake, receptor heterogeneity, and compensatory CXCR7 signaling remain important translational barriers.

• Merbromin Workflows for Fluorescence and Protease Assays

  2026-09-02

  Merbromin combines fluorescent protein-binding readouts with antimicrobial and viral-protease screening potential. This practical guide explains how to prepare, quantify, validate, and troubleshoot assays while keeping mercury-related safety and clinical translation limits in view.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ) Workflow

  2026-09-01

  Build reproducible mouse IL-12 expression studies with a capped, polyadenylated, m1Ψ-modified transcript designed for efficient translation and reduced RNA-driven innate activation. This practical guide connects bench-scale cytokine assays with emerging extrahepatic delivery strategies while clearly separating product specifications from experimental starting points.

• CUDC-907: Dual PI3K/HDAC Workflow Guide

  2026-08-31

  CUDC-907 is a dual PI3K and HDAC inhibitor for coordinated interrogation of PI3K/AKT signaling, histone acetylation, cell-cycle behavior, and apoptosis in cancer cell models. This guide covers preparation, controls, readouts, and troubleshooting for in vitro research; the compound is not intended for diagnostic, therapeutic, or clinical use.

• MK 0893 Glucagon Receptor Antagonist Workflow

  2026-08-31

  MK 0893 is a nanomolar, competitive reversible GCGR antagonist for connecting receptor pharmacology with glucose biology. This workflow covers compound handling, cAMP assay design, in vivo translation, selectivity controls, and troubleshooting for reproducible type 2 diabetes research.

• Linoleic Acid (C18:2): Practical Assay Guide

  2026-08-30

  Linoleic Acid (SKU C3108) provides a defined lipid input for oxidative stress, erythrocyte injury, membrane, migration, and nutritional deficiency workflows. It is suitable for solvent-based in vitro preparation but should not be treated as water-soluble or as a long-term stable aqueous stock.

• Chloroquine: From Lysosomal Signal to Assay Design

  2026-08-29

  Chloroquine research is strongest when lysosomal, mitochondrial, immune, and antiviral endpoints are interpreted together. This guide translates mechanistic evidence into practical assay-design decisions for cancer, malaria, and rheumatoid arthritis studies.

• Why Acute Myeloid Leukemia Responds to Mitocans

  2026-08-29

  The reference study identifies acute myeloid leukemia as unusually sensitive to mitochondria-targeting drugs and links this vulnerability to defective respiratory coupling. Its combination of NCI-60 analysis, mitochondrial phenotyping, cell-death assays, and primary AML testing supports a mechanistic model in which mitochondrial stress and glycolytic blockade can selectively damage leukemia cells.

• HyperScript™ Reverse Transcriptase for RT-qPCR

  2026-08-28

  Improve RNA to cDNA conversion when transcripts are scarce, long, or folded into difficult secondary structures. HyperScript™ Reverse Transcriptase supports practical cDNA synthesis for qPCR workflows, including pathway-focused cancer studies such as licoricidin research in hepatocellular carcinoma.

• Firefly Luciferase mRNA: Reliable Assay Design

  2026-08-28

  Learn how EZ Cap™ Firefly Luciferase mRNA (5-moUTP), SKU R1013, can strengthen reporter-based cell viability, proliferation, cytotoxicity, and translation studies. This scenario-driven guide covers assay interpretation, RNA handling, delivery compatibility, protocol controls, and practical vendor-selection criteria.

• Single-Molecule Imaging of R-Loop Collisions

  2026-08-27

  The reference study uses DNA-curtain single-molecule fluorescence imaging to observe how R-loops obstruct replication by Phi29 DNA polymerase. Its findings identify strand orientation, secondary structures, G-quadruplex formation, and residual T7 RNA polymerase as important determinants of replication stalling, providing a mechanistic framework for studying transcription–replication conflicts.

457 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page